Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients With Mild to Moderately Active Ulcerative Colitis

NCT06488625 is registered in ClinicalTrials.gov with University Hospital Schleswig-Holstein as lead sponsor.

NCT NCT06488625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06488625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients With Mild to Moderately Active Ulcerative Colitis
Lead sponsor
University Hospital Schleswig-Holstein
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 12, 2024
Completion date
December 31, 2027
Enrollment
459 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis, unspecified